Senator’s Wife Secretly Gave Him Psilocybin to Alleviate Depression
Senator Larry Campbell, who struggles with depression, PTSD, and “getting old,” reveals that psilocybin microdoses helped improve his mood.
Entries by James Hallifax
Psychedelic Capitalism Takes a Trip to Davos
From May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here’s why that matters for the psychedelics industry.
Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
A Brief History of MDMA: From the CIA to Raves to Psychedelic Therapy
The history of MDMA is fascinating, and it is still being written.
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
Wesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and industry at large.
Fungus Among Us: 5 Fascinating Facts About Mushrooms
Science just keeps discovering how cool and beneficial mushrooms are, with or without psilocybin.
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
Field Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
